Inflammatix Announces $32 Million in Series C Funding

Financing will be used to advance HostDx™ tests for acute infections and sepsis to commercial launch in 2021 BURLINGAME, Calif., Jan. 10, 2020 -- (Healthcare Sales & Marketing Network) -- Inflammatix, a pioneering molecular diagnostics company deliveri... Diagnostics, Venture Capital Inflammatix, HostDx, precision medicine, molecular diagnostics
Source: HSMN NewsFeed - Category: Pharmaceuticals Source Type: news